J&J Pledges $500m To Eliminate HIV and TB
A HIV vaccine is 'ultimate goal'
The healthcare giant is investing heavily into partnerships designed to beat the two infectious diseases.
You may also be interested in...
J&J ties up with agencies, Indian government to build capacity and widen access to Sirturo for TB patients.
US FDA's approval of the TB Alliance's pretomanid regimen for highly treatment-resistant tuberculosis comes with an LPAD designation and advisory committee-requested language to limit use.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.